You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
医药板块受捧跑赢 康希诺、京东健康、平安好医生及阿里健康涨8%-12%
Omicron新冠变种疫情于全球肆虐,尤其是欧洲及美国近期确诊病例急增,美国疫苗股默克(MRK.US)及辉瑞(PFE.US)上周五逆升1.9%及1.6%。 本港医药板块今早升幅远超大市,尤其是蓝筹阿里健康(00241.HK)由逾三年半低位连升第三天兼突破10天及20天线(6.67元),最高见7.16元,现报7.04元,急涨11.8%,为最强蓝筹;同业京东健康(06618.HK)及平安好医生(01833.HK)续升9%,分别高见62.75元及29.9元,股价升破20天线。 疫苗股康希诺生物-B(06185.HK)连升第二天兼一举升破50天、10天及20天线(166.3-170元),最高见180.9元,现报174.7元,续涨8%;复星医药(02196.HK)三连弹,最高见33.8元,现报33.5元,续升4.4%。 康方生物-B(09926.HK)续弹逾3%曾高见30.1元;百济神州(06160.HK)续弹3.6%曾高见141.9元。 信达生物(01801.HK)续弹4.5%报42元。蓝筹药明生物(02269.HK)续弹3.8%高见84.1元;药明康德(02359.HK)三连弹,最高见126元,现报122.4元,续升3.7%。 蓝筹石药(01093.HK)及中生制药(01177.HK)续涨近6%,分别高见9.43元及6.3元,股价升破百天线。此外,神威药业(02877.HK)续升4.6%高见7.08元;威高股份(01066.HK)续升4.6%曾高见10.42元。四环医药(00460.HK)回升7.5%报1.58元,股价重越50天线。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account